Search filters

Filters
Clear All

Phase

  • 12
  • 39
  • 2
  • 26
  • 1
  • 16
  • 1
  • 251
  • 352
  • 262
  • 4
  • 25
  • 323

Found 352 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Included Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FOLR1)
18 years or above
Female
Phase 2
The objectives of this study are to evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. In addition to this main objective, the study will also assess the additional efficacy outcome measures, as well as the safety and tolerability  of luveltamab tazevibulin in …
 Combination Ipatasertib and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer
18 years - 99 years
All genders
Phase 2
The purpose of this study is to determine if a combination of two drugs, Ipatasertib and Atezolizumab, works as a treatment for residual cancer in breast or lymph nodes and have circulating tumor DNA in blood. Eligible subjects will be those with triple negative breast cancer.
 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients with Newly Diagnosed or Recurrent Meningiomas
18 years - 99 years
All genders
Phase 3
This study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real time detection and visualization of meningiomas during tumor resection surgery. Potential patients who sign informed consent will be screened for eligibility before receiving an oral solution of Gleolan 3 hours prior to …
99 years or below
All genders
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
99 years or below
All genders
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence …
 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1  BRCA2 or PALB2 Mutation
18 years - 99 years
All genders
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …
 EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
18 years - 99 years
All genders
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it …
99 years or below
All genders
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
99 years or below
All genders
Phase 1
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
99 years or below
All genders
This study will evaluate safety, clinical activity, and PK of ZN-c3 in subjects with platinum-resistant, high grade, serous ovarian, fallopian tube, or primary peritoneal cancer. Part 1a locally advanced/metastatic solid tumors with mutations in MRN complex genes or CCNE1 gene amplification. Part 1b primary peritoneal cancer. Part 2: PROC allocated …
21 - 30 of 352